Report Highlights
This report is designed to investigate and discuss the latest developments in continuous glucose monitoring (CGM) for the management of diabetes. The study's goals include:
- Presenting the current products in the U.S., EU and elsewhere.
- Looking at the technology—both on the market and in development.
- Tracing improvements that companies are engineering and where these improvements may lead within the market.
- Examining how close the industry is to a device-based artificial pancreas (AP).
- Exploring selected clinical trials, the conclusions drawn from the research, and how the clinical trials affect the further development of CGM.
Report Includes
- An overview of the current state of the art for Continuous Glucose Monitoring (CGM) for diabetes
- Encompassing details of CGM functionalities like how they work, who can use one, and when a CGM could help to better manage the disease
- Insight into the key market dynamics (DROs), technology advancements, regulatory and reimbursement scenerio, and other market influencing factors
- Evaluation of market potential for CGM system and corresponding market share analysis by type of end user
- Review of selected clinical trials with relate to CGMs and related components such as sensors and pumps
- Company profile descriptions of the leading market participants
Report Scope
The scope of this study includes what a CGM is, how it works and how a PWD wears the device. This study also includes advances in the technology—both those advances being seen in the market today and advances for which CE mark or FDA approval is pending. There is a section covering the pancreas and diabetes, including the continued growth in the number of diabetics and prediabetics in the U.S. and elsewhere. It covers selected clinical trials pertinent to the evolution and proliferation of CGMs. The scope of this report includes novel CGMs and components in development. These may or may not ever see market launch but should nonetheless be of interest to industry managers.
Also covered here are selected regulatory and reimbursement affairs. Regulatory guidelines need to keep abreast of the technological developments so that safe, effective devices may enter the market. Without sufficient, carefully crafted reimbursement or payer coverage, the devices will never get off the ground. Both favorable regulatory and reimbursement guidelines are needed if manufacturers are to continue to develop and commercialize the best equipment for managing diabetes.
Selected companies are profiled in this report. These include not only the market leaders—Dexcom, Medtronic, Abbott, Tandem and Insulet—but also smaller companies working on promising technology.
Not covered in the scope of this report is in-depth analysis of market values and growth rates. These are available in other BCC Research reports. Also not covered is the ultimate in artificial pancreas: the cell-based implant. While these are under development, for practical purposes implants seem to be some distance down the road.
Analyst Credentials
Valerie Kellogg, RRT, BA, MS/MBA is an experienced medical device and pharmaceutical professional with international market research experience. She has authored numerous reports on topics ranging from the treatment of obesity to ablation devices, from wound care to the treatment of chronic migraine. Her strong focus areas include oncology, treatment of chronic disease, the latest in surgical devices and analysis of potential acquisitions in the medical device markets.
Related Reports
Continuous Glucose Monitoring (CGM): Technologies and Global Markets
The global CGM market should reach $20.7 billion by 2022 and $32.7 billion by 2027, with a compound annual growth rate (CAGR) of 9.5% during the forecast period of 2022-2027.
Home Health Monitoring Device Industry: Global Markets
The global market for home health monitoring systems should grow from $12.3 billion in 2020 to reach $29.1 billion by 2025, at a compound annual growth rate (CAGR) of 18.8% during the period of 2020-2025.
Latest Development, Product Innovations and Treatments for Diabetes
The global diabetes treatment market should grow from $80.9 billion in 2019 to $103.2 billion by 2024 at a compound annual growth rate (CAGR) of 5.0% for the period of 2019-2024.
Non-injectable Insulin
This comprehensive report provides an in-depth assessment of the global market for non-injectable insulin. The report's key objective is to analyze areas of opportunities, key developments and the impact of this technology on industry, specifically the pharmaceutical, biotechnology and healthcare sectors. The analysis also reviews the adoption of non-injectable insulin in developed and emerging markets.
Recent Reports
Conventional and Alternative Pain Treatment Markets
The global market for conventional and alternative pain treatment is expected to grow from $96.2 billion in 2024 and is projected to reach $144.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 8.4% during the forecast period of 2024 to 2029.
CRISPR Technology: Global Markets
The global market for CRISPR technology was valued at $3.4 billion in 2023. This market is expected to grow from $3.8 billion in 2024 to $7.5 billion by the end of 2029, at a compound annual growth rate (CAGR) of 14.4% from 2024 to 2029.
Chronic Disease Management: Therapeutics, Device Technologies and Global Markets
The global market for chronic disease management therapeutics and device technologies was valued at $675.0 billion in 2023. It is projected to grow from $726.3 billion in 2024 to $1.1 trillion by 2029, at a compound annual growth rate (CAGR) of 8.1% from 2024 through 2029.
Medical Devices: Technologies and Global Markets
The global market for medical devices reached $739.6 billion in 2023. It is expected to grow from $810.4 billion in 2024 to $1.3 trillion by the end of 2029, at a compound annual growth rate (CAGR) of 9.8% from 2024 through 2029.
Point-of-Care Diagnostics: Technologies and Global Markets
The global market for point-of-care diagnostics was valued at $36.9 billion in 2023. It is expected to grow from $40.6 billion in 2024 to $65.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 10.2% from 2024 through 2029.
Top Trending Reports
Single-use Technologies for Biopharmaceuticals: Global Markets
The global market for single-use technologies for biopharmaceuticals is expected to grow from $6.5 billion in 2024 and is projected to reach $11.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.6% during the forecast period of 2024 to 2029.
Cell and Gene Therapy Tools, and Reagents: Global Markets
The global market for Cell and Gene Therapy (CGT) Tools and Reagents is estimated to increase from $10.0 billion in 2024 to reach $16.7 billion by 2029, at a compound annual growth rate (CAGR) of 10.8% from 2024 through 2029.
Chronic Disease Management: Therapeutics, Device Technologies and Global Markets
The global market for chronic disease management therapeutics and device technologies was valued at $675.0 billion in 2023. It is projected to grow from $726.3 billion in 2024 to $1.1 trillion by 2029, at a compound annual growth rate (CAGR) of 8.1% from 2024 through 2029.
Global Market Opportunities and Competitive Landscape for CDMO
The global CDMO market was valued at $128.0 billion in 2023. This market is expected to grow from $136.6 billion in 2024 to $191.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2029.
CRISPR Technology: Global Markets
The global market for CRISPR technology was valued at $3.4 billion in 2023. This market is expected to grow from $3.8 billion in 2024 to $7.5 billion by the end of 2029, at a compound annual growth rate (CAGR) of 14.4% from 2024 to 2029.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More